The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs

Table 1

Basic characteristics of the included studies.

Study	ClinicalTrials.gov (number)	Phase		Treatment setting	Line of therapy	Median OS (months + 95% CI)	ORR (%)
Fuchs 2014 (REGARD)	NCT00917384	III	238	8 mg/kg RAM IV+BSC	2^nd line	5.2 (4.4 to 5.7)	3.4 (1.5 to 6.5)
			117	Placebo+BSC		3.8 (2.8 to 4.7)	2.6 (0.5 to 7.3)
Wilke2014 (RAINBOW)	NCT01170663	III	330	8 mg/kg RAM IV + 80 mg/m^2 PTX	2^nd line	9.6 (8.5 to 10.8)	27.9 (23.3 to 33.0)
			335	Placebo + 80 mg/m^2 PTX		7.4 (6.3 to 8.4)	16.1 (12.6 to 20.4)
Yoon 2016	NCT01246960	II	84	8 mg/kg RAM IV+mFOLFOX6	1^st line	11.7 (10.2 to 14.6)	45.2 (34.3 to 56.5)
			84	Placebo+mFOLFOX6		11.5 (9.0 to 15.3)	46.4 (35.5 to 57.6)
Yoshikawa 2019 (RAINSTORM)	NCT02539225	II	97	8 mg/kg RAM IV + 80-120 mg/m^2 S-1 + 100 mg/m^2 oxaliplatin	1^st line	14.65 (12.39 to 15.67)	58.2 (49.7 to 66.7)
			94	Placebo + 80-120 mg/m^2 S-1 + 100 mg/m^2 oxaliplatin		14.26 (13.83 to 17.31)	50.0 (41.3 to 58.7)
Fuchs 2019 (RAINFALL)	NCT02314117	III	326	8 mg/kg RAM IV + 80 mg/m^2 cisplatin IV + 1000 mg/m^2 capecitabine	1^st line	11.17 (9.92 to 11.93)	41.1 (35.8 to 46.4)
			319	Placebo + 80 mg/m^2 cisplatin IV + 1000 mg/m^2 capecitabine		10.74 (9.53 to 11.89)	36.4 (31.1 to 41.6)

ORR: objective response rate; OS: overall survival; RAM: ramucirumab; BSC: best supportive care; PTX: paclitaxel; mFOLFOX6: administered IV per manufacturer’s instructions for each drug substance on day 1 of each cycle (14 days/cycle). Oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-fluorouracil (5-FU) 400 mg/m² bolus 5-FU 2400 mg/m², 5-FU 2400 mg/m² continuously given over 46–48 h; S-1: tegafur-gimeracil-oteracil potassium.